✦ LIBER ✦

PCN30 IMPROVED TOXICITY PROFILE OF PEMETREXEDVS DOCETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS TRANSLATES TO COST SAVINGS IN SPAIN

✍ Scribed by G Stynes; M Aristides; R Rosell; E Felip; AM Liepa

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

99 Efficacy and toxicity profile of gemc

✍ Guerra, J.A.; Lianes, P.; Paz-Ares, L.; Castellano, D.; Gómez-Martín, C.; Cortés 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 149 KB

PCN58 A COST UTILITY ANALYSIS OF ERLOTIN

✍ PA Bradbury; R Jang; P Isogai; R Ng; N Mittmann; W Evans; FA Shepherd; NB Leighl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PCN8 AVERAGE TOTAL COST OF TREATING ADVA

✍ A Kielhorn; M Aristides; DP Tilden; S Bhalla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

769 Reducing health care burden for the

✍ L. Bushill-Matthews; D. Jackson; M. Aristides; J. von Pawel; F. De Marines; R. G 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 147 KB

PCN46 COST SAVINGS RELATED TO SUPERIOR A

✍ D Heigener; HG Bischoff; K Banz; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVER

✍ J de Castro Carpeño; K Banz; AJ Castro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB